Status:
UNKNOWN
Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH
Lead Sponsor:
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Conditions:
Allogeneic Stem Cell Transplantation
Eligibility:
All Genders
Brief Summary
The allogeneic hematopoietic stem cell marrow is the only curative treatment for many hematologic malignancies. However, many patients relapse in these situations to be therapeutic possibilities scarc...
Detailed Description
It reviewed 350 patients who underwent allogeneic 2 or more between the beginning of monitoring and the end of 2009, end of follow-up. Is a multicenter study of row should include all possible patient...
Eligibility Criteria
Inclusion
- patients who underwent 2 or more allogeneic transplants and the beginning of monitoring and the end of 2009, end of follow-up.
Exclusion
- \-
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT01212796
Start Date
September 1 2010
End Date
June 1 2011
Last Update
October 1 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.